Synergistic anti-tumor effects of combined IL-1/IFN-alpha/beta therapy in mice injected with metastatic Friend erythroleukemia cells.
Peritumoral injection of relatively low doses of either mouse interferon (IFN)-alpha/beta (10,000-20,000 units/injection) or of recombinant human interleukin-1 (IL-1) beta (125-250 ng/injection) in mice transplanted s.c. with Friend erythroleukemia cells (FLC) resulted in some inhibition of primary tumor growth, inhibition of liver and splenic metastases and increased survival time. A synergistic anti-tumor effect was observed in mice injected with both IL-1 and IFN-alpha/beta. Highly purified mouse IFN-beta also exerted a synergistic anti-tumor effect when combined with IL-1-beta in mice injected with FLC. The anti-tumor action of IL-1/IFN was markedly reduced in mice treated with antibodies to CD4 antigens. Antibodies to asialo-GM1 also diminished the anti-tumor effect by the combined cytokine treatment. The combined IL-1/IFN therapy was effective in NK-deficient bg/bg mice, although the extent of the anti-tumor response in these mice was less than that observed in bg/+mice.
Belardelli
F
F
Laboratory of Virology, Istituto Superiore di Sanità, Rome, Italy.
Gabriele
L
L
Proietti
E
E
Sestili
P
P
Peretti
M
M
Rozera
C
C
Gresser
I
I
D000818:Animals; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D007108:Immune Tolerance; D007370:Interferon Type I / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000627:therapeutic use*; D004915:Leukemia, Erythroblastic, Acute / Q000628:therapy*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA; D014407:Tumor Cells, Cultured
D007370:Interferon Type I; D007375:Interleukin-1